Evidence map›Paper›PMID 20966122›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2011

FGF-23 as a predictor of renal outcome in diabetic nephropathy.

Silvia M Titan, Roberto Zatz, Fabiana G Graciolli, Luciene M dos Reis, Rui T Barros, Vanda Jorgetti, Rosa M A Moysés

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 3 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?Clinical journal of the American Society of Nephrology : CJASN · 2010
    Trial
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Non-Classical Effects of FGF23: Molecular and Clinical Features.International journal of molecular sciences · 2024
    Review
  15. The therapeutic effect of mesenchymal stem cells in diabetic kidney disease.Journal of molecular medicine (Berlin, Germany) · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Silvia M TitanSao Paulo University Medical School, Av Dr Enéas de Carvalho Aguiar, 255, Nephrology Department, 05403-000, São Paulo, SP, Brazil. silviatitan@superig.com.br
Roberto Zatz
Fabiana G Graciolli
Luciene M dos Reis
Rui T Barros
Vanda Jorgetti
Rosa M A Moysés
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesFibroblast growth factor 23 (FGF-23) has emerged as a new factor in mineral metabolism in chronic kidney disease (CKD). An important regulator of phosphorus homeostasis, FGF-23 has been shown to independently predict CKD progression in nondiabetic renal disease. We analyzed the relation between FGF-23 and renal outcome in diabetic nephropathy (DN). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: DN patients participating in a clinical trial (enalapril+placebo versus enalapril+losartan) had baseline data collected and were followed until June 2009 or until the primary outcome was reached. Four patients were lost to follow-up. The composite primary outcome was defined as death, doubling of serum creatinine, and/or dialysis need.

resultsAt baseline, serum FGF-23 showed a significant association with serum creatinine, intact parathyroid hormone, proteinuria, urinary fractional excretion of phosphate, male sex, and race. Interestingly, FGF-23 was not related to calcium, phosphorus, 25OH-vitamin D, or 24-hour urinary phosphorus. Mean follow-up time was 30.7±10 months. Cox regression showed that FGF-23 was an independent predictor of the primary outcome, even after adjustment for creatinine clearance and intact parathyroid hormone (10 pg/ml FGF-23 increase = hazard ratio, 1.09; 95% CI, 1.01 to 1.16, P=0.02). Finally, Kaplan-Meier analysis showed a significantly higher risk of the primary outcome in patients with FGF-23 values of >70 pg/ml.

conclusionsFGF-23 is a significant independent predictor of renal outcome in patients with macroalbuminuric DN. Further studies should clarify whether this relation is causal and whether FGF-23 should be a new therapeutic target for CKD prevention.

Indexed as

AgedAlbuminuriaAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiomarkersBrazilChi-Square DistributionDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationEnalaprilFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiomarkersEnalaprilFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsLosartan

Identifiers

PMID20966122
PMCPMC3052212
OpenAlexW2122584551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.